Results 41 to 50 of about 240,836 (199)

Improving Patient Safety Through Proper Ordering and Administration of Andexanet Alfa [PDF]

Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Objective: To evaluate prescribing practices for the anti-Xa reversal agent, andexanet alfa, to identify challenges in ordering and administering this medication, and to offer recommendations to improve patient safety.
Krystof Stanek, MD, Mohammad T. Hussain, MD, Aaron C. Spaulding, PhD, Shalmali Borkar, MD, MPH, Marwan E. Shaikh, MD   +4 more
doaj   +2 more sources

Andexanet alfa vs standard of care for factor Xa inhibitor-induced intracranial hemorrhage-a systematic review and meta-analysis. [PDF]

Res Pract Thromb Haemost
Background Direct oral anticoagulants are activated factor (F)X (FXa) or thrombin inhibitors. Patients on FXa inhibitors are at increased risk for major bleeding events that require anticoagulation reversal.
Xiang AJ, Sadafi SL, Principato R, Shaikh A, Nowrouzi M, Eshaghpour A, Li A, Crowther M.   +7 more
europepmc   +2 more sources

Andexanet alfa for reversal of intracerebral haemorrhage resulting in ST-segment myocardial infarction: a case report. [PDF]

Eur Heart J Case Rep
Background Direct oral anticoagulants, such as direct factor Xa inhibitors, are commonly used to treat and prevent blood clots in patients with atrial fibrillation.
Mehrara S, Patel R, DeRon N.
europepmc   +2 more sources

Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint [PDF]

Cardiology Journal, 2023
Jacek Kubica, Piotr Adamski, Robert Gajda, Mariusz Gąsior, Marek Gierlotka, Robert Gil, Miłosz Jaguszewski, Aldona Kubica, Wiktor Kuliczkowski, Krzysztof Kurek, Jerzy Robert Ładny, Piotr Michalski, Eliano Pio Navarese, Piotr Niezgoda, Małgorzata Ostrowska, Agnieszka Tycińska   +15 more
doaj   +2 more sources

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

Clinical and Applied Thrombosis/Hemostasis, 2022
Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors.
Alex C. Spyropoulos MD, Bríain Ó Hartaigh PhD, Zhun Cao PhD, MA, Harjeet Caberwal PharmD, Craig Lipkin MS, Michaela Petrini PA-C, MHS, Cheng Wang MD, PhD   +6 more
doaj   +1 more source

Real-World Observational Review of Andexanet Alfa Prescribing and Utilization Outcomes at a Community Teaching Hospital

Critical Care Explorations, 2021
Objectives:. Andexanet alfa is the first approved antidote in the management of life-threatening bleeds in patients treated with Xa inhibitors. The ANNEXA-4 study was successful in reducing factor Xa levels during time of administration but lacked ...
Kristine A. Sobolewski, PharmD, BCPS, Alison Brophy, PharmD, BCPS, BCCCP, Seohyun (Claudia) Choi, PharmD, BCCCP, Yekaterina Opsha, PharmD, BCPS-AQ Cardiology, AACC, FHFSA   +3 more
doaj   +1 more source

Andexanet alfa-induced heparin resistance during percutaneous coronary intervention for ST-elevation myocardial infarction: a case report. [PDF]

Eur Heart J Case Rep
Background Andexanet alfa is a recombinant modified factor Xa decoy protein used to reverse the anticoagulant effects of direct oral factor Xa inhibitors, including apixaban, rivaroxaban, and edoxaban.
Sasaki S, Matsumoto D, Takeshige R, Iwata S.   +3 more
europepmc   +2 more sources

In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra

Research and Practice in Thrombosis and Haemostasis, 2022
Background Both andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) are clinically applied reversal agents for direct factor Xa inhibitors (FXaIs) in emergency situations. Controversy exists whether 4F‐PCC is as effective as andexanet
Herm Jan M. Brinkman, Marleen Zuurveld, Joost C. M. Meijers   +2 more
doaj   +1 more source

Institutional Experience of Using Andexanet Alfa [PDF]

Cureus, 2020
Given their ease of use, safety, and efficacy, direct-acting oral anticoagulants (DOACs) are nowadays widely used in patients with atrial fibrillation or venous thromboembolism, with or without an association with malignancy. Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that reverses the inhibition of factor Xa ...
Khadka, Sushmita, Kasireddy, Vineela, Dhakal, Pravash   +2 more
openaire   +2 more sources

Evaluation of anticoagulation re-initiation practices following reversal of factor Xa inhibitors with andexanet alfa or 4F-PCC in patients with major bleeding events

Thrombosis Update, 2021
Background: Both andexanet alfa and 4F-PCC reversal strategies have been associated with thrombotic events. It remains unclear whether the risk is associated with the reversal agent or the lack of re-initiation of anticoagulation.
Awatif Hafiz, Alshaya Abdulrahman I, Katelyn W. Sylvester, Jean M. Connors, Jessica Rimsans   +4 more
doaj   +1 more source